GlassScriptPhysician profile
Thomas C Caves
NPI 1144284522
$4,651.09
in general payments reported to CMS, 2019-2025
24 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $274 · 2021: $329 · 2022: $216 · 2023: $260 · 2024: $566 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,309.02 | 2019-2025 | Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.59 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $451.63 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $377.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $329.75 | 2019-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $273.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $231.82 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $133.99 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $126.11 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $121.19 | 2025 | Vowst, Zenpep |
| Genzyme Corporation | $114.35 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.49 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $97.31 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $89.76 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $87.46 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $71.38 | 2021-2023 | Sutab |
| Boston Scientific Corporation | $67.31 | 2022-2025 | Cinchpad |
| Shionogi INC | $44.16 | 2019 | |
| Daiichi Sankyo INC. | $34.76 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $31.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.76 | 2023 | Andexxa |
| Portola Pharmaceuticals, LLC | $20.47 | 2019 | |
| Allergan, INC. | $19.75 | 2019 | |
| Celgene Corporation | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Caves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.